Add to the mix;;
Recently W & R sold their patent rights to STEM,, on the cheap,, which could have been an attempt to mitigate any attempt by STEM to sue them for damages.. That deal could require W & R to testify at any related trial at STEM's request,,
AND,, hopefully Dr. T has the same MINDSET as Dr Feldman...
Be nice if the Dr. Maurizio Fava peer review abstract for NSI 189 was published before the R&R -----early look very encouraging" ---
And,, add in some low-hanging-fruit.. OA & RA have approx 3 billion potential patients,, at 10k profit per..
???--- has there ever been a company with a Trillion dollar market cap ????
When you were at the July hearing was there any discussions about cell types? We keep seeing posts about
arguments concerning different cell types.. Near as I can tell the patent of interest deals with the Technique for Proliferation of Nerve Cells for Transplantation,, or simply multiplying nerve cells ..
***** 1991 Re: Technique for Proliferation of Nerve Cells for Transplantation
***** This letter is to indicate the allotment of interests ""to the inventors"" of the above invention:
AND,, the patent agreement has in it's script,, proliferation of "NERVE CELLS" .. Are all STEM CELLS classified as nerve cells?? If not there is a ton of low hanging fruit using stem cells,, which could be easier to get approvals for.. Could be another use-reason for CUR to pursue,, if they aren't already...
target @$8 --????
If the Dr. Maurizio Fava NSI-189 abstract is published next month,, and the results are as good as aura suggests,, and a partner for 189 is found shortly after,,,, HMMMMM ...
My guess would be a $50. 1 yr target ,, $20 YE...
f-times,, some add-ons to the patents value..
Dr. Teztlaff sold his share of the patents much cheaper that did W & R ,, ????
STEM'S use of the patents does not support-demonstrate much intrinsic patent value!!
And from RS;;
CUR has never had a negative clinical data press release, and this is not because it spins data. It’s a testament to the high quality of its science.
""Only the highest quality science has a chance of succeeding in these difficult neurodegenerative diseases.""
Did not think I would ever say this because we learn so much from discussions,, even including the airheads..
But maybe there should be a private discussion website where everyone could read but only invite-ie's could post..
Could always come back to this mb to rebut the nonsense.. Might even get TG to return...
FAST ------ So what else could Judge Titus be looking for with his Dec. Trial?? If he is looking to charge the SOAP OPERA GROUP with fraud,, they just won't appear,, then he will need to rule on what facts he already has.. Or maybe that is his plan,, the final nail or a negotiated sharing of the patent..
From a recent post;;---- TO THE INVENTORS,,,,
1991 Re: Technique for Proliferation of Nerve Cells for Transplantation
This letter is to indicate the allotment of interests ""to the inventors"" of the above invention:
45% - Dr. Samuel Weiss, Dept. of Pathology
45% - Mr. Brent Alan Williams, Dept. of Pathology
10% - Dr. Wolfram Tetzlaff, Dept. of Anatomy"
Unless there is some fraud involved in this MOU,, Weiss & Williams should be trying to cut a deal to avoid criminal charges...
Not an expert,, but a little history..
The last phase of the HEAT TRIAL used an SPA -- special protocol assessment -- which would allow for an
approval using a progression formula,, which was not met.. The SPA was negotiated with the FDA after the agency suggested CLSN skip phase 2 and go to a phase 3 SPA.. To the best of my knowledge OS has always been the primary end point.. Even if the SPA had been a success,, OS end point still had to be met..
For a subgroup of 285 patients. For this group, clinical results indicate a 57% improvement in OS, a Hazard Ratio of 0.639 (95% CI 0.419 – 0.974), and a p-value of 0.037. --- "Median overall survival for this subgroup has not yet been reached..
When Median overall survival is reached, possibility exists for an NDA for this subgroup.. JMO..
Should be an interesting upcoming CC in 2 weeks...
Yes & no !!! ---
CUR incorporated in 1997 in the state of Maryland and re-incorporated in the state of Delaware in 2001..
In Delaware company managements are virtual dictators regarding corp decisions.. And even if you agree with the current management,, what happens if they die in a plane crash,, what will the next managers do with that power ?????
IT IS WHAT IT IS !!!!!!!
Actually I was referring to the DIGNITY STUDY .. With P2 confirming P1,, and no other treatment available ,, Either the FDA or CLSN should be considering the BTD application..
As to the HEAT STUDY,, the section of the trial treating 5 to 7cm HCC,, combined with the safety profile of TDOX,, which allows for multiple treatments,, which could turn HCC into a chronic disease should also be considered for BTD...
The FDA's new "breakthrough" product designation allows new drugs to win approval after just a single round of testing, instead of the usual three. -----"A breakthrough drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.
And,, if the agency is seeing promise in trial results,, they can ask the trial sponsor to apply for BTD..
no2,, a ? ,,, is it not just as important to know that the hippocampus stopped growing when nsi189 was stopped.. Don't need any more fatheads to care for...